A Phase 2 interventional study of Tislelizumab and Ociperlimab in Non Small Cell Lung Cancer, sponsored by BeiGene. Completed at 14 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.
Sponsored by BeiGene · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 22 under way, 2 of them phase 3. tislelizumab · Carcinoma, Non-Small-Cell Lung.
Among the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, this one is the 11th largest by enrollment, is one of 6 that started in 2023, is one of 26 in phase 2, and was the 17th registered.
7,624 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →20 of the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–75
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18+
Fujian Cancer Hospital · Sites in China
Ages 18–75
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
Sun Yat-sen University · Sites in China
Ages 18–75
By country, each count listing its studies:
tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 28 · Phase 3 10 · Phase 4 2
First in 2017; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 121 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 39 across the 41 interventional studies. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 41 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
16 studies in Carcinoma, Non-Small-Cell Lung by BeOne Medicines: none open now, 1 under way, 1 of them phase 3. Of 15 finished, 10 (67%) have results posted.
Among the 16 studies in Carcinoma, Non-Small-Cell Lung by BeOne Medicines, this one is the 11th largest by enrollment, is one of 4 that started in 2023, is one of 4 in phase 2, and was the 11th registered.
BeOne Medicines’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2017.
2 of the studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07320105Fujian Cancer HospitalPostoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II) | 2027-01-15 |
| NCT07845916Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyQuad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among BeOne Medicines’s 16 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This study was conducted to evaluate the preliminary effectiveness and safety of treatment with tislelizumab alone and in combination with other investigational agents prior to surgery (neoadjuvant treatment) in adults with non-small cell lung cancer (NSCLC) that is able to be removed by surgery.
This is a randomized, open-label, multicenter, Phase 2, umbrella study to evaluate the preliminary efficacy, safety, and pharmacodynamics of tislelizumab as monotherapy and in combination with investigational agents as neoadjuvant treatment in Chinese participants with resectable Stage II to IIIA NSCLC. The study is designed with the flexibility of adding treatment arms as new treatments become available or discontinuing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, and of modifying the participant population.
The study consisted of a neoadjuvant treatment phase (2 - 4 cycles of treatment), a surgery phase and a follow-up phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with tumor programmed death protein ligand-1 (PD-L1) expression ≥ 50% received 200 mg tislelizumab intravenously once every 3 weeks for 2-4 cycles followed by surgical removal of the tumor.
Drug: Tislelizumab
Participants with tumor PD-L1 expression ≥ 50% received 200 mg tislelizumab and 900 mg ociperlimab intravenously once every 3 weeks for 2-4 cycles followed by surgical removal of the tumor.
Drug: Tislelizumab · Drug: Ociperlimab
Participants with tumor PD-L1 expression ≥ 50% received 200 mg tislelizumab and 600 mg alcestobart intravenously once every 3 weeks for 2-4 cycles followed by surgical removal of the tumor.
Drug: Tislelizumab · Drug: Alcestobart
Participants with tumor PD-L1 expression \< 50% received 200 mg tislelizumab and chemotherapy consisting of cisplatin or carboplatin with either pemetrexed or paclitaxel administered intravenously once every 3 weeks for 2-4 cycles followed by surgical removal of the tumor.
Drug: Tislelizumab · Drug: Cisplatin · Drug: Carboplatin · Drug: Pemetrexed · Drug: Paclitaxel
Participants with tumor PD-L1 expression \< 50% received 200 mg tislelizumab, 600 mg alcestobart and chemotherapy consisting of cisplatin or carboplatin with either pemetrexed or paclitaxel administered intravenously once every 3 weeks for 2-4 cycles followed by surgical removal of the tumor.
Drug: Tislelizumab · Drug: Alcestobart · Drug: Cisplatin · Drug: Carboplatin · Drug: Pemetrexed · Drug: Paclitaxel
Administered as an intravenous infusion once every 3 weeks
Also known as: BGB-A317, Tevimbra
Administered as an intravenous infusion once every 3 weeks
Also known as: BGB-A1217
Administered as an intravenous infusion once every 3 weeks
Also known as: LBL-007
75 mg/m\^2 administered as an intravenous infusion once every 3 weeks
Administered as an intravenous infusion once every 3 weeks at an area under the curve (AUC) of 5 mg/mL/min
500 mg/m\^2 administered as an intravenous infusion once every 3 weeks in participants with non-squamous NSCLC
175 mg/m\^2 administered as an intravenous infusion once every 3 weeks in participants with squamous NSCLC
Major Pathological Response (MPR) Rate
Tumor tissue and lymph node tissue obtained from surgical resection were sent to a central laboratory according to study pathology manuals for pathological response analysis. MPR rate is defined as the percentage of participants with ≤ 10% residual viable tumor in the resected primary tumor and all resected lymph nodes as assessed by blinded independent pathology review (BIPR). Participants without surgery or pathological results were considered non-responders.
Time frame: At the time of surgery, approximately Week 16
Pathological Complete Response (pCR)
Pathological complete response is defined as the percentage of participants with absence of residual tumor in the resected primary tumor and all resected lymph nodes as assessed by the BIPR. Participants without surgery or pathological results were considered as non-responders.
Time frame: At the time of surgery, approximately Week 16
Event-free Survival (EFS)
EFS is defined as the time from randomization until any of the following events, whichever occurred first: radiographic disease progression that precludes definitive surgery, local or distant recurrence as assessed by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause. Local recurrence is defined as recurrence in the ipsilateral thorax (lymph node or lung on the same side as Baseline location) including lung parenchyma, bronchial stump, main trachea, hilum or mediastinal lymph nodes (including subcarinal lymph nodes), pleura and chest wall diagnosed by radiological examination and/or histopathological confirmation. Distant recurrence (metastasis) is defined as spread of disease beyond the area of the ipsilateral thorax (including contralateral area and other organs) diagnosed by radiological examination and/or histopathological confirmation. Median EFS was estimated using Kaplan-Meier methodology.
Time frame: From randomization until the end of study, maximum time on study was 22 months in Substudy 1 and 13 months in Substudy 2.
Event-free Survival Rate
Event-free survival rate is defined as the percentage of participants with none of the following events: radiographic disease progression that precludes definitive surgery, local or distant recurrence as assessed by investigator per RECIST v1.1, or death due to any cause. Local recurrence is defined as recurrence in the ipsilateral thorax (lymph node or lung on the same side as Baseline location) including lung parenchyma, bronchial stump, main trachea, hilum or mediastinal lymph nodes (including subcarinal lymph nodes), pleura and chest wall diagnosed by radiological examination and/or histopathological confirmation. Distant recurrence (metastasis) is defined as spread of disease beyond the area of the ipsilateral thorax (including contralateral area and other organs) diagnosed by radiological examination and/or histopathological confirmation. EFS rates were estimated using the Kaplan-Meier method with the corresponding 95% confidence interval constructed using Greenwood's formula.
Time frame: 12 months and 24 months after randomization
Overall Survival (OS)
OS is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using Kaplan-Meier methodology.
Time frame: From randomization until the end of study, maximum time on study was 22 months in Substudy 1 and 13 months in Substudy 2.
Overall Survival Rate
Overall survival rate is defined as the percentage of participants who were still alive at the analysis time points. OS rates were estimated using the Kaplan-Meier method with the corresponding 95% confidence interval constructed using Greenwood's formula.
Time frame: 12 months and 24 months after randomization
Disease-free Survival (DFS)
DFS is defined as the time from the first date of no disease (ie, participants who underwent margin-negative \[R0\] resection) to local or distant recurrence, as assessed by the investigator according to RECIST v1.1, or death due to any cause, whichever occurred first. Median DFS was estimated using Kaplan-Meier methodology.
Time frame: From randomization until the end of study, maximum time on study was 22 months in Substudy 1 and 13 months in Substudy 2.
Disease-free Survival Rate
Disease-free survival rate is defined as the percentage of participants with none of the following events: Local or distant recurrence as assessed by the investigator per RECIST v1.1, or death due to any cause. Local recurrence is defined as recurrence in the ipsilateral thorax (lymph node or lung on the same side as Baseline location) including lung parenchyma, bronchial stump, main trachea, hilum or mediastinal lymph nodes (including subcarinal lymph nodes), pleura and chest wall diagnosed by radiological examination and/or histopathological confirmation. Distant recurrence (metastasis) is defined as spread of disease beyond the area of the ipsilateral thorax (including contralateral area and other organs) diagnosed by radiological examination and/or histopathological confirmation. DFS rates were estimated using the Kaplan-Meier method with the corresponding 95% confidence interval constructed using Greenwood's formula.
Time frame: 12 months and 24 months after randomization
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
A serious adverse event (SAE) is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the investigator or sponsor based on medical judgement (eg, may have jeopardized the participant or may require medical/surgical intervention to prevent one of the outcomes listed above). Immune-mediated adverse events (imAEs) are autoimmune-mediated complications that may develop in response to immunotherapeutic agents. Immune-mediated AEs were collected from the date of first dose of study drug to 90 days after the last dose of study drug, regardless of whether the participant started a new anticancer therapy or prespecified adjuvant treatment. imAEs were identified by the investigator based on a standard process defined in the Protocol.
Time frame: From first dose of study drug until 30 days after last dose or new anticancer treatment, whichever occurred first, or up to 90 days after the last dose for imAEs; maximum duration of treatment was 14 weeks.
Feasibility of Surgery
Feasibility of surgery was assessed by the number of participants who underwent surgical resection (surgery) within 6 weeks of last dose of study drug, had delayed or canceled surgery, the approach of surgery, duration of surgery (see next outcome measure) ,and the number of participants who underwent an exploratory thoracotomy, a surgical procedure in which a cut is made between the ribs to see and reach the lungs or other organs in the chest or thorax. Exploratory thoracotomy was not counted as surgery.
Time frame: At the time of surgery, approximately Week 16
Duration of Surgery
The duration of surgery is defined as the time interval from the start of the surgical procedure to its completion.
Time frame: Approximately Week 16
This study enrolled 121 participants at study sites in China.
| Milestone | Arm 1A: Tislelizumab Monotherapy | Arm 1B: Tislelizumab + Ociperlimab | Arm 1C: Alcestobart + Tislelizumab | Arm 2A: Tislelizumab and Chemotherapy | Arm 2C: Alcestobart + Tislelizumab + Chemotherapy |
|---|---|---|---|---|---|
| Started | 20 | 20 | 20 | 20 | 41 |
| Treated | 20 | 20 | 20 | 19 | 40 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 20 | 20 | 20 | 20 | 41 |
| Withdrew: Study ended by sponsor | 19 | 17 | 19 | 16 | 38 |
| Withdrew: Death | 1 | 2 | 1 | 3 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 1 | 1 |
Tumor tissue and lymph node tissue obtained from surgical resection were sent to a central laboratory according to study pathology manuals for pathological response analysis. MPR rate is defined as the percentage of participants with ≤ 10% residual viable tumor in the resected primary tumor and all resected lymph nodes as assessed by blinded independent pathology review (BIPR). Participants without surgery or pathological results were considered non-responders.
| percentage of participants | Arm 1A: Tislelizumab Monotherapy | Arm 1B: Tislelizumab + Ociperlimab | Arm 1C: Alcestobart + Tislelizumab | Arm 2A: Tislelizumab and Chemotherapy | Arm 2C: Alcestobart + Tislelizumab + Chemotherapy |
|---|---|---|---|---|---|
| Major Pathological Response (MPR) Rate | 45.0 (23.1 to 68.5) | 50.0 (27.2 to 72.8) | 40.0 (19.1 to 63.9) | 55.0 (31.5 to 76.9) | 34.1 (20.1 to 50.6) |
Pathological complete response is defined as the percentage of participants with absence of residual tumor in the resected primary tumor and all resected lymph nodes as assessed by the BIPR. Participants without surgery or pathological results were considered as non-responders.
| percentage of participants | Arm 1A: Tislelizumab Monotherapy | Arm 1B: Tislelizumab + Ociperlimab | Arm 1C: Alcestobart + Tislelizumab | Arm 2A: Tislelizumab and Chemotherapy | Arm 2C: Alcestobart + Tislelizumab + Chemotherapy |
|---|---|---|---|---|---|
| Pathological Complete Response (pCR) | 30.0 (11.9 to 54.3) | 30.0 (11.9 to 54.3) | 40.0 (19.1 to 63.9) | 35.0 (15.4 to 59.2) | 17.1 (7.2 to 32.1) |
EFS is defined as the time from randomization until any of the following events, whichever occurred first: radiographic disease progression that precludes definitive surgery, local or distant recurrence as assessed by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause. Local recurrence is defined as recurrence in the ipsilateral thorax (lymph node or lung on the same side as Baseline location) including lung parenchyma, bronchial stump, main trachea, hilum or mediastinal lymph nodes (including subcarinal lymph nodes), pleura and chest wall diagnosed by radiological examination and/or histopathological confirmation. Distant recurrence (metastasis) is defined as spread of disease beyond the area of the ipsilateral thorax (including contralateral area and other organs) diagnosed by radiological examination and/or histopathological confirmation. Median EFS was estimated using Kaplan-Meier methodology.
| months | Arm 1A: Tislelizumab Monotherapy | Arm 1B: Tislelizumab + Ociperlimab | Arm 1C: Alcestobart + Tislelizumab | Arm 2A: Tislelizumab and Chemotherapy | Arm 2C: Alcestobart + Tislelizumab + Chemotherapy |
|---|---|---|---|---|---|
| Event-free Survival (EFS) | NA (10.3 to NA) | NA (3.7 to NA) | 11.4 (11.4 to NA) | 11.6 (7.9 to NA) | NA (10.9 to NA) |
Event-free survival rate is defined as the percentage of participants with none of the following events: radiographic disease progression that precludes definitive surgery, local or distant recurrence as assessed by investigator per RECIST v1.1, or death due to any cause. Local recurrence is defined as recurrence in the ipsilateral thorax (lymph node or lung on the same side as Baseline location) including lung parenchyma, bronchial stump, main trachea, hilum or mediastinal lymph nodes (including subcarinal lymph nodes), pleura and chest wall diagnosed by radiological examination and/or histopathological confirmation. Distant recurrence (metastasis) is defined as spread of disease beyond the area of the ipsilateral thorax (including contralateral area and other organs) diagnosed by radiological examination and/or histopathological confirmation. EFS rates were estimated using the Kaplan-Meier method with the corresponding 95% confidence interval constructed using Greenwood's formula.
| percentage of participants | Arm 1A: Tislelizumab Monotherapy | Arm 1B: Tislelizumab + Ociperlimab | Arm 1C: Alcestobart + Tislelizumab | Arm 2A: Tislelizumab and Chemotherapy | Arm 2C: Alcestobart + Tislelizumab + Chemotherapy |
|---|---|---|---|---|---|
| 12 months | 75.3 (24.5 to 94.4) | 60.0 (17.8 to 86.0) | 44.0 (1.1 to 86.1) | 0.0 (NA to NA) | 50.5 (15.0 to 78.2) |
| 24 months | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 0.0 (NA to NA) | NA (NA to NA) |
OS is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using Kaplan-Meier methodology.
| months | Arm 1A: Tislelizumab Monotherapy | Arm 1B: Tislelizumab + Ociperlimab | Arm 1C: Alcestobart + Tislelizumab | Arm 2A: Tislelizumab and Chemotherapy | Arm 2C: Alcestobart + Tislelizumab + Chemotherapy |
|---|---|---|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) | NA (11.4 to NA) | NA (11.6 to NA) | NA (NA to NA) |
Overall survival rate is defined as the percentage of participants who were still alive at the analysis time points. OS rates were estimated using the Kaplan-Meier method with the corresponding 95% confidence interval constructed using Greenwood's formula.
| percentage of participants | Arm 1A: Tislelizumab Monotherapy | Arm 1B: Tislelizumab + Ociperlimab | Arm 1C: Alcestobart + Tislelizumab | Arm 2A: Tislelizumab and Chemotherapy | Arm 2C: Alcestobart + Tislelizumab + Chemotherapy |
|---|---|---|---|---|---|
| 12 months | 91.7 (53.9 to 98.8) | 89.7 (64.8 to 97.3) | 90.0 (47.3 to 98.5) | 58.6 (8.4 to 89.2) | 94.9 (81.2 to 98.7) |
| 24 months | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
DFS is defined as the time from the first date of no disease (ie, participants who underwent margin-negative \[R0\] resection) to local or distant recurrence, as assessed by the investigator according to RECIST v1.1, or death due to any cause, whichever occurred first. Median DFS was estimated using Kaplan-Meier methodology.
| months | Arm 1A: Tislelizumab Monotherapy | Arm 1B: Tislelizumab + Ociperlimab | Arm 1C: Alcestobart + Tislelizumab | Arm 2A: Tislelizumab and Chemotherapy | Arm 2C: Alcestobart + Tislelizumab + Chemotherapy |
|---|---|---|---|---|---|
| Disease-free Survival (DFS) | NA (8.4 to NA) | NA (8.0 to NA) | NA (8.8 to NA) | 8.7 (4.0 to NA) | NA (9.0 to NA) |
Disease-free survival rate is defined as the percentage of participants with none of the following events: Local or distant recurrence as assessed by the investigator per RECIST v1.1, or death due to any cause. Local recurrence is defined as recurrence in the ipsilateral thorax (lymph node or lung on the same side as Baseline location) including lung parenchyma, bronchial stump, main trachea, hilum or mediastinal lymph nodes (including subcarinal lymph nodes), pleura and chest wall diagnosed by radiological examination and/or histopathological confirmation. Distant recurrence (metastasis) is defined as spread of disease beyond the area of the ipsilateral thorax (including contralateral area and other organs) diagnosed by radiological examination and/or histopathological confirmation. DFS rates were estimated using the Kaplan-Meier method with the corresponding 95% confidence interval constructed using Greenwood's formula.
| percentage of participants | Arm 1A: Tislelizumab Monotherapy | Arm 1B: Tislelizumab + Ociperlimab | Arm 1C: Alcestobart + Tislelizumab | Arm 2A: Tislelizumab and Chemotherapy | Arm 2C: Alcestobart + Tislelizumab + Chemotherapy |
|---|---|---|---|---|---|
| 12 months | 75.0 (12.8 to 96.1) | 60.6 (7.5 to 90.8) | 50.0 (0.6 to 91.0) | 0.0 (NA to NA) | NA (NA to NA) |
| 24 months | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 0.0 (NA to NA) | NA (NA to NA) |
A serious adverse event (SAE) is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the investigator or sponsor based on medical judgement (eg, may have jeopardized the participant or may require medical/surgical intervention to prevent one of the outcomes listed above). Immune-mediated adverse events (imAEs) are autoimmune-mediated complications that may develop in response to immunotherapeutic agents. Immune-mediated AEs were collected from the date of first dose of study drug to 90 days after the last dose of study drug, regardless of whether the participant started a new anticancer therapy or prespecified adjuvant treatment. imAEs were identified by the investigator based on a standard process defined in the Protocol.
| Participants | Arm 1A: Tislelizumab Monotherapy | Arm 1B: Tislelizumab + Ociperlimab | Arm 1C: Alcestobart + Tislelizumab | Arm 2A: Tislelizumab and Chemotherapy | Arm 2C: Alcestobart + Tislelizumab + Chemotherapy |
|---|---|---|---|---|---|
| Any TEAE | 7 | 14 | 15 | 19 | 39 |
| Serious adverse events | 0 | 3 | 2 | 2 | 13 |
| Immune-mediated AEs | 0 | 6 | 3 | 2 | 17 |
Feasibility of surgery was assessed by the number of participants who underwent surgical resection (surgery) within 6 weeks of last dose of study drug, had delayed or canceled surgery, the approach of surgery, duration of surgery (see next outcome measure) ,and the number of participants who underwent an exploratory thoracotomy, a surgical procedure in which a cut is made between the ribs to see and reach the lungs or other organs in the chest or thorax. Exploratory thoracotomy was not counted as surgery.
| Participants | Arm 1A: Tislelizumab Monotherapy | Arm 1B: Tislelizumab + Ociperlimab | Arm 1C: Alcestobart + Tislelizumab | Arm 2A: Tislelizumab and Chemotherapy | Arm 2C: Alcestobart + Tislelizumab + Chemotherapy |
|---|---|---|---|---|---|
| Underwent Surgery | 16 | 14 | 12 | 17 | 31 |
| Received open surgery | 4 | 5 | 6 | 4 | 9 |
| Received minimally invasive surgery | 12 | 9 | 6 | 13 | 22 |
| Received Exploratory Thoracotomy | 1 | 0 | 0 | 1 | 0 |
| Delayed Surgery | 7 | 3 | 3 | 2 | 8 |
| No Surgery or Exploratory Thoracotomy | 3 | 6 | 8 | 1 | 9 |
The duration of surgery is defined as the time interval from the start of the surgical procedure to its completion.
| hours | Arm 1A: Tislelizumab Monotherapy | Arm 1B: Tislelizumab + Ociperlimab | Arm 1C: Alcestobart + Tislelizumab | Arm 2A: Tislelizumab and Chemotherapy | Arm 2C: Alcestobart + Tislelizumab + Chemotherapy |
|---|---|---|---|---|---|
| Duration of Surgery | 3.33 (2.5 to 5.3) | 3.50 (2.3 to 5.3) | 3.39 (2.3 to 8.7) | 4.30 (2.7 to 8.0) | 4.05 (2.0 to 6.6) |
Collected over Deaths were collected from randomization up to the end of study; maximum time on study was 22 months in Substudy 1 and 13 months in Substudy 2. Adverse events were collected from first dose of study drug until 30 days after last dose or new anticancer treatment, whichever occurred first, or up to 90 days after the last dose for imAEs; maximum duration of treatment was 14 weeks.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1A: Tislelizumab Monotherapy | 1/20 (5%) | 0/20 (0%) | 7/20 (35%) |
| Arm 1B: Tislelizumab + Ociperlimab | 2/20 (10%) | 3/20 (15%) | 14/20 (70%) |
| Arm 1C: Alcestobart + Tislelizumab | 1/20 (5%) | 2/20 (10%) | 14/20 (70%) |
| Arm 2A: Tislelizumab and Chemotherapy | 3/20 (15%) | 2/19 (10.5%) | 19/19 (100%) |
| Arm 2C: Alcestobart + Tislelizumab + Chemotherapy | 2/41 (4.9%) | 13/40 (32.5%) | 38/40 (95%) |
| Event | Arm 1A: Tislelizumab Monotherapy | Arm 1B: Tislelizumab + Ociperlimab | Arm 1C: Alcestobart + Tislelizumab | Arm 2A: Tislelizumab and Chemotherapy | Arm 2C: Alcestobart + Tislelizumab + Chemotherapy |
|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/20 | 0/20 | 0/20 | 1/19 | 1/40 |
| HypokalaemiaMetabolism and nutrition disorders | 0/20 | 0/20 | 0/20 | 1/19 | 0/40 |
| ThrombocytosisBlood and lymphatic system disorders | 0/20 | 0/20 | 1/20 | 0/19 | 0/40 |
| Myocardial injuryCardiac disorders | 0/20 | 1/20 | 0/20 | 0/19 | 0/40 |
| HyperthyroidismEndocrine disorders | 0/20 | 1/20 | 0/20 | 0/19 | 0/40 |
| Subarachnoid haemorrhageNervous system disorders | 0/20 | 1/20 | 0/20 | 0/19 | 0/40 |
| Immune-mediated dermatitisSkin and subcutaneous tissue disorders | 0/20 | 0/20 | 1/20 | 0/19 | 0/40 |
| AnaemiaBlood and lymphatic system disorders | 0/20 | 0/20 | 0/20 | 0/19 | 1/40 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/20 | 0/20 | 0/20 | 0/19 | 1/40 |
| LeukopeniaBlood and lymphatic system disorders | 0/20 | 0/20 | 0/20 | 0/19 | 1/40 |
| Event | Arm 1A: Tislelizumab Monotherapy | Arm 1B: Tislelizumab + Ociperlimab | Arm 1C: Alcestobart + Tislelizumab | Arm 2A: Tislelizumab and Chemotherapy | Arm 2C: Alcestobart + Tislelizumab + Chemotherapy |
|---|---|---|---|---|---|
| Neutrophil count decreasedInvestigations | 2/20 | 0/20 | 0/20 | 16/19 | 27/40 |
| White blood cell count decreasedInvestigations | 2/20 | 0/20 | 0/20 | 12/19 | 20/40 |
| AnaemiaBlood and lymphatic system disorders | 1/20 | 3/20 | 4/20 | 10/19 | 23/40 |
| NauseaGastrointestinal disorders | 0/20 | 1/20 | 1/20 | 7/19 | 7/40 |
| Aspartate aminotransferase increasedInvestigations | 0/20 | 3/20 | 4/20 | 7/19 | 10/40 |
| LeukopeniaBlood and lymphatic system disorders | 0/20 | 0/20 | 0/20 | 6/19 | 14/40 |
| Platelet count decreasedInvestigations | 1/20 | 0/20 | 0/20 | 6/19 | 7/40 |
| Decreased appetiteMetabolism and nutrition disorders | 0/20 | 1/20 | 1/20 | 3/19 | 11/40 |
| Alanine aminotransferase increasedInvestigations | 0/20 | 2/20 | 4/20 | 5/19 | 10/40 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/20 | 0/20 | 0/20 | 4/19 | 10/40 |
| Age, Continuous(years) | Arm 1A: Tislelizumab Monotherapy | Arm 1B: Tislelizumab + Ociperlimab | Arm 1C: Alcestobart + Tislelizumab | Arm 2A: Tislelizumab and Chemotherapy | Arm 2C: Alcestobart + Tislelizumab + Chemotherapy | Total |
|---|---|---|---|---|---|---|
| Mean | 63.5 ± 6.68 | 63.1 ± 6.78 | 62.7 ± 8.03 | 61.0 ± 6.86 | 61.9 ± 9.76 | 62.3 ± 8.03 |
| Sex: Female, Male(Participants) | Arm 1A: Tislelizumab Monotherapy | Arm 1B: Tislelizumab + Ociperlimab | Arm 1C: Alcestobart + Tislelizumab | Arm 2A: Tislelizumab and Chemotherapy | Arm 2C: Alcestobart + Tislelizumab + Chemotherapy | Total |
|---|---|---|---|---|---|---|
| Female | 2 | 1 | 3 | 3 | 10 | 19 |
| Male | 18 | 19 | 17 | 17 | 31 | 102 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1A: Tislelizumab Monotherapy | Arm 1B: Tislelizumab + Ociperlimab | Arm 1C: Alcestobart + Tislelizumab | Arm 2A: Tislelizumab and Chemotherapy | Arm 2C: Alcestobart + Tislelizumab + Chemotherapy | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 20 | 20 | 20 | 20 | 41 | 121 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Arm 1A: Tislelizumab Monotherapy | Arm 1B: Tislelizumab + Ociperlimab | Arm 1C: Alcestobart + Tislelizumab | Arm 2A: Tislelizumab and Chemotherapy | Arm 2C: Alcestobart + Tislelizumab + Chemotherapy | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 20 | 20 | 20 | 20 | 41 | 121 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Arm 1A: Tislelizumab Monotherapy | Arm 1B: Tislelizumab + Ociperlimab | Arm 1C: Alcestobart + Tislelizumab | Arm 2A: Tislelizumab and Chemotherapy | Arm 2C: Alcestobart + Tislelizumab + Chemotherapy | Total |
|---|---|---|---|---|---|---|
| 0 (Fully Active) | 9 | 7 | 8 | 9 | 22 | 55 |
| 1 (Ambulatory with Restricted Activities) | 11 | 13 | 12 | 11 | 19 | 66 |
| Smoking Status(Participants) | Arm 1A: Tislelizumab Monotherapy | Arm 1B: Tislelizumab + Ociperlimab | Arm 1C: Alcestobart + Tislelizumab | Arm 2A: Tislelizumab and Chemotherapy | Arm 2C: Alcestobart + Tislelizumab + Chemotherapy | Total |
|---|---|---|---|---|---|---|
| Current | 3 | 1 | 4 | 2 | 5 | 15 |
| Former | 15 | 15 | 12 | 15 | 22 | 79 |
| Never | 2 | 4 | 4 | 3 | 14 | 27 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Begene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. Beigene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for Beigene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · beigene.com
Ran from Mar 2023 to primary completion in Dec 2024, 21 months.
Results were first posted in Feb 2026, 1 year 1 month after primary completion.
Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 21 months is below that.
Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tislelizumab
Carcinoma, Non-Small-Cell Lung →